Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 2, pp. e003026-e003026
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
Barbara Burtness, Danny Rischin, Richard Greil, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 21, pp. 2321-2332
Open Access | Times Cited: 155
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Kevin J. Harrington, Robert L. Ferris, Maura L. Gillison, et al.
JAMA Oncology (2023) Vol. 9, Iss. 6, pp. 779-779
Open Access | Times Cited: 47
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Alessandra Cesano, Ryan C. Augustin, Luigi Barrea, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e008876-e008876
Open Access | Times Cited: 2
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline
Emrullah Yilmaz, Nofisat Ismaila, Julie E. Bauman, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 5, pp. 1132-1146
Open Access | Times Cited: 54
Biomarkers predictive of response to pembrolizumab in head and neck cancer
David G. Pfister, Robert I. Haddad, Francis P. Worden, et al.
Cancer Medicine (2022) Vol. 12, Iss. 6, pp. 6603-6614
Open Access | Times Cited: 32
Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
Jong Chul Park, Hari N. Krishnakumar, Srinivas Vinod Saladi
Current Oncology (2022) Vol. 29, Iss. 6, pp. 4185-4198
Open Access | Times Cited: 29
Immunotherapy in Head and Neck Cancer: Where Do We Stand?
Natalia G. Vallianou, Angelos Evangelopoulos, Dimitris Kounatidis, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 8, pp. 897-912
Closed Access | Times Cited: 19
The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers
S Mestiri, Dina Moustafa Abo El-Ella, Queenie Fernandes, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116095-116095
Open Access | Times Cited: 8
Neutrophil‐to‐lymphocyte ratio associates with nutritional parameters, intratumoral immune profiles, and clinical outcomes of pembrolizumab in head and neck squamous cell carcinoma
Hiroki Morimoto, Takahiro Tsujikawa, Aya Miyagawa‐Hayashino, et al.
Head & Neck (2024) Vol. 46, Iss. 8, pp. 1956-1964
Closed Access | Times Cited: 6
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
Kohei Shitara, Maria Di Bartolomeo, Mario Mandalà, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006920-e006920
Open Access | Times Cited: 15
Targeted Proteomic Quantitation of NRF2 Signaling and Predictive Biomarkers in HNSCC
Nathan Wamsley, Emily Wilkerson, Li Guan, et al.
Molecular & Cellular Proteomics (2023) Vol. 22, Iss. 11, pp. 100647-100647
Open Access | Times Cited: 14
The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy
Jing Yi Lee, Bavani Kannan, Boon Yee Lim, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 7839-7839
Open Access | Times Cited: 19
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
Mara Serena Serafini, Stefano Cavalieri, Lisa Licitra, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007823-e007823
Open Access | Times Cited: 3
Impact of COL11A1 Mutations on Tumor Mutational Signatures and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma
Angela Yee‐Moon Wang, Jin Cheng, Jing Xiao
Cureus (2025)
Open Access
Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma
Niki Gavrielatou, Ioannis Vathiotis, Thazin Nwe Aung, et al.
Cancer Research Communications (2023) Vol. 3, Iss. 4, pp. 558-563
Open Access | Times Cited: 9
Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review
Amirhossein Tamimi, Atena Tamimi, Fatemeh Sorkheh, et al.
Cancer Reports (2023) Vol. 6, Iss. 5
Open Access | Times Cited: 9
Biomarkers and experimental models for cancer immunology investigation
Hengyi Xu, Ziqi Jia, Fengshuo Liu, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 8
Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review
Lei Wang, Yingyu Huang, Xin Sun
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
ATM Inhibition-Induced ISG15/IFI27/OASL Is Correlated with Immunotherapy Response and Inflamed Immunophenotype
Chi-Han Huang, Yun-Cian Huang, Jun-Kai Xu, et al.
Cells (2023) Vol. 12, Iss. 9, pp. 1288-1288
Open Access | Times Cited: 7
Deciphering the role of HPV-mediated metabolic regulation in shaping the tumor microenvironment and its implications for immunotherapy in HNSCC
Xiangjin Gong, Jingwen Xiong, Yu Gong, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Alan L. Ho
Journal of Clinical Oncology (2022) Vol. 41, Iss. 4, pp. 736-741
Open Access | Times Cited: 12
Molecular subtyping of head and neck cancer – Clinical applicability and correlations with morphological characteristics
Fabian Stögbauer, Raik Otto, Korinna Jöhrens, et al.
Oral Oncology (2024) Vol. 149, pp. 106678-106678
Open Access | Times Cited: 2
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy
Ze Zhang, Kartik Sehgal, Keisuke Shirai, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Closed Access | Times Cited: 2
Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis
Yue Zheng, Baijie Feng, Jingyao Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives
Amaury Daste, Mathieu Larroquette, Nyere Gibson, et al.
Immunotherapy (2023) Vol. 16, Iss. 3, pp. 187-197
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top